Molecular pathways: The immunogenic effects of platinum-based chemotherapeutics

Clinical Cancer Research

Volumn 20, Issue 11, 2014, Pages 2831-2837

  Hato, Stanleyson V ^a   Khong, Andrea ^b   De Vries, I Jolanda M ^a   Lesterhuis, W Joost ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CALRETICULIN; CARBOPLATIN; CISPLATIN; HIGH MOBILITY GROUP B1 PROTEIN; IPILIMUMAB; OXALIPLATIN; PACLITAXEL; PLATINUM COMPLEX; PROGRAMMED DEATH 1 LIGAND 1; SOMATOMEDIN B RECEPTOR; STAT PROTEIN; ANTINEOPLASTIC AGENT; PLATINUM DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENICITY; IMMUNOMODULATION; LUNG NON SMALL CELL CANCER; METASTATIC MELANOMA; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; IMMUNOLOGY; NEOPLASMS;

ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; PLATINUM COMPOUNDS;

EID: 84901744815     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-3141     Document Type: Article

References (60)

1. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007;7:573-84. (Pubitemid 47106628)
2. Wang K, Lu J, Li R. The events that occur when cisplatin encounters cells. Coord Chem Rev 1996;151:53-88.
3. Jordan P, Carmo-Fonseca M. Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci 2000;57:1229-35. (Pubitemid 30663480)
4. Todd RC, Lippard SJ. Inhibition of transcription by platinum antitumor compounds. Metallomics 2009;1:280-91.
5. Jamieson ER, Lippard SJ. Structure, Recognition, and Processing of Cisplatin-DNA Adducts. Chem Rev 1999;99:2467-98.
6. Sorenson CM, Eastman A. Influence of cis-diamminedichloroplatinum (II) on DNA synthesis and cell cycle progression in excision repair proficient and deficient Chinese hamster ovary cells. Cancer Res 1988;48:6703-7. (Pubitemid 19012192)
7. Fraval HN, Roberts JJ. Excision repair of cis- diamminedichloroplatinum(II)-induced damage to DNA of Chinese hamster cells. Cancer Res 1979;39:1793-7. (Pubitemid 9171842)
8. Hoebers FJ, Pluim D, Verheij M, Balm AJ, Bartelink H, Schellens JH, et al. Prediction of treatment outcome by cisplatin-DNA adduct formation in patients with stage III/IV head and neck squamous cell carcinoma, treated by concurrent cisplatin-radiation (RADPLAT). Int J Cancer 2006;119:750-6. (Pubitemid 44051437)
9. Welters MJ, Fichtinger-Schepman AM, Baan RA, Jacobs-Bergmans AJ, Kegel A, van der Vijgh WJ, et al. Pharmacodynamics of cisplatin in human head and neck cancer: correlation between platinum content, DNA adduct levels and drug sensitivity in vitro and in vivo. Br J Cancer 1999;79:82-8. (Pubitemid 28566930)
10. Brouwer J, van de Putte P, Fichtinger-Schepman AM, Reedijk J. Base-pair substitution hotspots in GAG and GCG nucleotide sequences in Escherichia coli K-12 induced by cis-diamminedichloroplatinum (II). Proc Natl Acad Sci U S A 1981;78:7010-4. (Pubitemid 12216835)
11. Akaboshi M, Kawai K, Maki H, Akuta K, Ujeno Y, Miyahara T. The number of platinum atoms binding to DNA, RNA and protein molecules of HeLa cells treated with cisplatin at its mean lethal concentration. Jpn J Cancer Res 1992;83:522-6.
12. Harder HC, Rosenberg B. Inhibitory effects of anti-tumor platinum compounds on DNA, RNA and protein syntheses in mammalian cells in vitro. Int J Cancer 1970;6:207-16.
13. Jung Y, Lippard SJ. Direct cellular responses to platinum-inducedDNA damage. Chem Rev 2007;107:1387-407. (Pubitemid 46864967)
14. Fuertes MA, Alonso C, Perez JM. Biochemical modulation of Cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance. Chem Rev 2003;103:645-62.
15. Saris CP, van de Vaart PJ, Rietbroek RC, Blommaert FA. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells. Carcinogenesis 1996;17:2763-9. (Pubitemid 27037637)
16. Bose RN. Biomolecular targets for platinum antitumor drugs. Mini Rev Med Chem 2002;2:103-11.
17. Hostetter AA, Osborn MF, DeRose VJ. RNA-Pt adducts following cisplatin treatment of Saccharomyces cerevisiae. ACS Chem Biol 2012;7:218-25.
18. Chapman EG, DeRose VJ. Enzymatic processing of platinated RNAs. J Am Chem Soc 2010;132:1946-52.
19. Hostetter AA, Chapman EG, DeRose VJ. Rapid cross-linking of anRNA internal loop by the anticancer drug cisplatin. J Am Chem Soc 2009;131:9250-7.
20. Zou J, An F, Liu G, Wang K. The Binding of Platinum (II) Complexes to Rabbit Skeletal Muscle G-Actin Induces Conformation Changes. Met Based Drugs 1995;2:233-40.
21. Williams JP, Phillips HI, Campuzano I, Sadler PJ. Shape changes induced by N-terminal platination of ubiquitin by cisplatin. J Am Soc Mass Spectrom 2010;21:1097-106.
22. Ishida R, Takaoka Y, Yamamoto S, Miyazaki T, Otaka M, Watanabe S, et al. Cisplatin differently affects amino terminal and carboxyl terminal domains of HSP90. FEBS Lett 2008;582:3879-83.
23. Kopf-Maier P, Muhlhausen SK. Changes in the cytoskeleton pattern of tumor cells by cisplatin in vitro . Chem Biol Interact 1992;82:295-316.
24. Bose RN, Maurmann L, Mishur RJ, Yasui L, Gupta S, Grayburn WS, et al. Non-DNA-binding platinum anticancer agents: Cytotoxic activities of platinum-phosphato complexes towardshuman ovarian cancer cells. Proc Natl Acad Sci U S A 2008;105:18314-9.
25. Lesterhuis WJ, Haanen JB, Punt CJ. Cancer immunotherapy - revisited. Nat Rev Drug Discov 2011;10:591-600.
26. Lesterhuis WJ, Punt CJ, Hato SV, Eleveld-Trancikova D, Jansen BJ, Nierkens S, et al. Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J Clin Invest 2011;121:3100-8.
27. Loke P, Allison JP. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci U S A 2003;100:5336-41. (Pubitemid 36542706)
28. Hato SV, de Vries IJ, Lesterhuis WJ. STATing the importance of immune modulation by platinum chemotherapeutics. Oncoimmunology 2012;1:234-6.
29. Song H, Sondak VK, Barber DL, Reid TJ, Lin J. Modulation of Janus kinase 2 by cisplatin in cancer cells. Int J Oncol 2004;24:1017-26.
30. Turkson J, Zhang S, Mora LB, Burns A, Sebti S, Jove R. A novel platinum compound inhibits constitutive Stat3 signaling and induces cell cycle arrest and apoptosis of malignant cells. J Biol Chem 2005; 280:32979-88. (Pubitemid 41368347)
31. Littlefield SL, Baird MC, Anagnostopoulou A, Raptis L. Synthesis, characterization and Stat3 inhibitory properties of the prototypical platinum(IV) anticancer drug, [PtCl3(NO2)(NH3)2] (CPA-7). Inorg Chem 2008;47:2798-804.
32. Turkson J, Zhang S, Palmer J, Kay H, Stanko J, Mora LB, et al. Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Mol Cancer Ther 2004;3:1533-42. (Pubitemid 40136708)
33. Kim HJ, Oh GS, Lee JH, Lyu AR, Ji HM, Lee SH, et al. Cisplatin ototoxicity involves cytokines and STAT6 signaling network. Cell Res 2011;21:944-56.
34. Kaur T, Mukherjea D, Sheehan K, Jajoo S, Rybak LP, Ramkumar V. Short interfering RNA against STAT1 attenuates cisplatin-induced ototoxicity in the rat by suppressing inflammation. Cell Death Dis 2011;2:e180.
35. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007;13:1050-9. (Pubitemid 47517504)
36. Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 2010;29:482-91.
37. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013;31:51-72.
38. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007;13:54-61. (Pubitemid 46067386)
39. Panaretakis T, Kepp O, Brockmeier U, Tesniere A, Bjorklund AC, Chapman DC, et al. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J 2009;28:578-90.
40. Elliott MR, Chekeni FB, Trampont PC, Lazarowski ER, Kadl A, Walk SF, et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 2009;461:282-6.
41. Idzko M, Hammad H, van Nimwegen M, Kool M, Willart MA, Muskens F, et al. Extracellular ATP triggers and maintains asthmatic airway inflammation by activating dendritic cells. Nat Med 2007;13:913-9. (Pubitemid 47222044)
42. Granstein RD, Ding W, Huang J, Holzer A, Gallo RL, Di Nardo A, et al. Augmentation of cutaneous immune responses by ATP gamma S: purinergic agonists define a novel class of immunologic adjuvants. J Immunol 2005;174:7725-31. (Pubitemid 40806278)
43. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 2010;28: 367-88.
44. Obeid M, Panaretakis T, Joza N, Tufi R, Tesniere A, van Endert P, et al. Calreticulin exposure is required for the immunogenicity of gamma-irradiation andUVClight-induced apoptosis. Cell Death Differ 2007;14:1848-50. (Pubitemid 47423653)
45. Martins I, Kepp O, Schlemmer F, Adjemian S, Tailler M, Shen S, et al. Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene 2011;30:1147-58.
46. Ciampricotti M, Hau CS, Doornebal CW, Jonkers J, de Visser KE. Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system. Nat Med 2012;18:344-6.
47. Zitvogel L, Kroemer G. Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system reply. Nat Med 2012;18:344-6.
48. Ramakrishnan R, Assudani D, Nagaraj S, Hunter T, Cho HI, Antonia S, et al. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest 2010; 120:1111-24.
49. Liu WM, Fowler DW, Smith P, Dalgleish AG. Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br J Cancer 2010; 102:115-23.
50. Vasaturo A, Di Blasio S, Peeters DGA, De Koning CCH, De Vries J, Figdor C, et al. Clinical implications of co-inhibitory molecule expression in the tumor microenvironment for DC vaccination: a game of stop and go. Front Immunol 2013;4:417.
51. Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012;30:2046-54.
52. Reck M, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol 2013; 24:75-83.
53. Wu L, Yun Z, Tagawa T, Rey-McIntyre K, de Perrot M. CTLA-4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy in murine mesothelioma. Mol Cancer Ther 2012;11:1809-19.
54. Lesterhuis WJ, Salmons J, Nowak AK, Rozali EN, Khong A, Dick IM, et al. Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity. PLoS ONE 2013;8:e61895.
55. Rizvi NA, Antonia SJ, Chow LQM, Brahmer JR, Juergens RA, Borghaei H, et al. A phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naive non-small cell lung cancer (NSCLC) patients (pts). J Clin Oncol 31, 2013 (suppl; abstr 8072).
56. Lesterhuis WJ, de Vries IJ, Aarntzen EA, de Boer A, Scharenborg NM, van de Rakt M, et al. A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients. Br J Cancer 2010;103:1415-21.
57. Harrop R, Drury N, Shingler W, Chikoti P, Redchenko I, Carroll MW, et al. Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. Clin Cancer Res 2007;13:4487-94. (Pubitemid 47219718)
58. Kang TH, Mao CP, Lee SY, Chen A, Lee JH, Kim TW, et al. Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity. Cancer Res 2013;73:2493-504.
59. Menger L, Vacchelli E, Adjemian S, Martins I, Ma Y, Shen S, et al. Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. Sci Transl Med 2012;4:143ra99.
60. Kepp O, Menger L, Vacchelli E, Adjemian S, Martins I, Ma Y, et al. Anticancer activity of cardiac glycosides: At the frontier between cell-autonomous and immunological effects. Oncoimmunology 2012;1: 1640-2.